Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Grows By 17.6%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 450,000 shares, an increase of 17.6% from the August 31st total of 382,600 shares. Based on an average daily trading volume, of 116,500 shares, the short-interest ratio is currently 3.9 days.

Hedge Funds Weigh In On Milestone Pharmaceuticals

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BNP Paribas Financial Markets boosted its stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 177.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,900 shares of the company’s stock after purchasing an additional 10,800 shares during the quarter. BNP Paribas Financial Markets’ holdings in Milestone Pharmaceuticals were worth $30,000 at the end of the most recent reporting period. 86.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 22nd. They set a “buy” rating and a $9.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Thursday, August 22nd.

Milestone Pharmaceuticals Stock Performance

MIST stock traded up $0.01 during midday trading on Monday, reaching $1.54. 6,404 shares of the company were exchanged, compared to its average volume of 209,502. The company has a debt-to-equity ratio of 1.61, a current ratio of 19.13 and a quick ratio of 19.13. The business has a 50-day moving average price of $1.45 and a two-hundred day moving average price of $1.54. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $3.52. The firm has a market capitalization of $82.02 million, a price-to-earnings ratio of -1.22 and a beta of 1.71.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Equities research analysts forecast that Milestone Pharmaceuticals will post -0.71 EPS for the current year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.